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Abstract
Aim: To study nanocomposite-based conjugate of ferromagnet and cisplatin pharmacokinetic parameters and its 
therapeutic pathomorphosis in rats with sensitive and DDP-resistant Guerin’s carcinoma.
Material and Methods: The female Wistar rats with sensitive and DDP-resistant Guerin’s carcinoma received a 
nanocomposite-based conjugate of a ferromagnet and DDPonce at dose 3.5mg of DDP/kg intraperitoneally. All 
animals were anesthetized and samples of blood, tumour, liver and kidneys were collectedat 0.25, 0.5, 1, 3, 6 and 
24h after the injection. Deposition of iron and platinum were measured using atomic absorption spectroscopy, AUC 
was calculated by trapezoidal method. 
Results: In both sensitive and resistant strains of Guerin’scarcinonma, maximum concentriation of Pt in tumor tissue 
and blood serum was measured after at 1h after ingection of a nanocomposite-based conjugate of a ferromagnet and 
DDP. Pharmacokinetic studies found that agent accumulated 2.6 times more intensely in the DDP-resistanttumor 
tissue rather in sensitive. Introduction of studied agent in the therapeutic regimen leads to inhibiti on of the growth 
of DDP-resistant Guerin’scarcinoma, which is accompanied by the appearance of signs of medical pathomorphosis.
Conclusion: Pharmacokinetic studies have established that ferromagnetic nanocomposite accumulates more intensively 
in a resistant tumor and cause the most significant manifestations of therapeutic pathomorphosis compared to a 
sensitive tumor.
Keywords: Resistance, Ferromagnetic Nanocomposite, 
Pharmacokinetics, Cisplatin
Abbreviations: DDP – cisplatin, S – sensitive Guerin’s carcinoma 
strain, R – DDP-resistant Guerin’s carcinoma strain, platinum – Pt, 
iron - Fe
Introduction
One of the main problems of modern oncopharmacology is low 
selective efficiency and high systemic toxicity of anticancer drugs. 
Side effects in the treatment of cancer patients are often a limiting 
factor in therapy and can cause complications, which lead to lethal 
consequences in more than 20% of cases [1-3]. An active search of 
approaches to increase the selectivity of cytostatics and reduce their 
toxicity to organs and tissues that are not affected by the tumor has 
resulted by a new generation of targeted drugs based on humanized 
monoclonal antibodies [4-6].
However, the optimization of cytostatic therapy by the use of modern 
biotechnology does not allow to reduce the toxicity of the most 
common drugs and to offer methods to overcome the key problem of 
modern clinical oncology - resistance of tumors to antitumor drugs 
[7,8]. The formation of resistance to different types of cytostatics 
involves complex and numerical mechanisms associated with 
thedecrease of drugs accumulation in malignant cells and with the 
enhancement of their removal from cells, the activation of complex 
detoxification systems, repair of damaged DNA, cell deviation from 
the inclusion of apoptotic program etc. [9-12]. These processes 
significantly affect the change in the cytostatics pharmacokinetics, 
in particular, their bioavailability, and, consequently, therapeutic 
efficacy. Our previous studies have shown that a change in the 
pharmacokinetics of cisplatin (DDP) can achieve a significant 
reduction in its toxicity and increase selectivity [13].
Recent studies have shown the significant role of metal-containing 
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proteins and their receptors in the processes of pharmacodynamics 
and biotransformation of DDP and in the mechanisms of formation 
of cell resistance to this cytostatic [14-17]. It has been established 
that during the development of cancer cells resistance the level of 
merging the Fe2+ -containing compounds increases significantly due 
to a significant increase in the level of transferrin and its receptors, 
as well as heavy and light ferritin chains [15]. This allowed us to 
begin the search for exogenous factors of DDPpharmacocorrection, 
as one of the most common drug in cancer patients chemotherapy 
[18,19]. Attracting nanotechnologies has made it possible to create a 
nanocomposite - a new medicine based on a conjugate ferromagnet 
and cisplatin (Feroplat®) [20].
In in vivo experiments on ascitic models of Ehrlich and L1210 
carcinomas and solid tumors of carcinosarcoma Walker-256 and 
Guerin’s carcinoma we have shown that the antitumor activity of 
Feroplat®exceeds the efficacy of DDP. At the same time, the toxicity 
of the nanocomposite to the target organ cells was much lower 
compared to the effect of DDP itself [21-23].
Taking into account the above, in order to find out the mechanisms 
underlying the increase of selectivity and decrease of toxic effects 
of DDP, we have conducted a study of the pharmacokinetics of 
Feroplat®in animals with sensitive (S) and DDP-resistant (R)
Guerin’s carcinoma.
MaterialsandMethods
Feroplat® synthesis
Synthesis of Feroplat® was carried out by a liquid-phase method, 
based on the co-precipitation of two- and trivalent iron salts by 
aqueous ammonia solution [24].
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                                       Figure 1: Scheme of ferromagnetic nanocomposite (Feroplat®) obtaining technology
The DDP adsorption onthe surface of the nanoparticles of the 
magnetic fluid was carried out for the Fe3O4/oleate Na (magnetic 
fluid) system. In order to increase stability and reduce aggregation 
of particles, the resulting magnetic fluid with adsorbed cytostatics 
was additionally modified with polyethylene glycol (PEG-2000).
At each stage of synthesis, the physical, chemical and magnetic 
properties of the developed nanocomposite were monitored. The 
obtained nanoparticle size distributions made it possible to characterize 
the synthesized nanocomposite as a monodispersionwith the size 
of 30-40 nm. The concentration of Fe3O4 in the nanocompositewas 
determined using atomic emission spectrometry method and was3 
mg/ml and the concentration of DDP – 0.4 mg/ml.
In vivo study
The study was performed on 60 female Wistar rats with body 
weight of 145 - 155 g according to the International Guidelines 
of Work with laboratory Animals approved by Bioethics 
Committee of R.E. Kavetsky IEPOR NASU (Kyiv, Ukraine). 
Guerin’scarcinomas(sensitive and DDP-resistant strains) were 
transplanted subcutaneously intotheinterscapular region by injection 
of 0.5 ml of tumor cell suspension (2x106 cells per animal).All 
animals werekeptintemperature-controlled,sterilizedanimalquarte
rsunder a 12 h light:12 h darkcycle.
Pharmacokineticsand bioavailability study design
To study the pharmacokinetics of Feroplat®, the animals were 
divided into 2 groups: rats with sensitive and DDP-resistant Guerin’s 
carcinoma. The tumor was transplanted as described above. The 
intraperitoneal Feroplat® dose was 3.5 mg of DDP/kg body weight. 
At time points of 0.25 h, 0.5 h, 1 h, 3 h, 6 h and 24 h after injection, 
the animals were withdrawn from the experiment and samples of 
blood, tumor, liver, and kidneys were taken.
The bioavailability of Feroplat®, as well as the degree of accumulation 
of Pt and iron in the serum, tumor tissue, liver and kidneys of rats 
with sensitive and DDP-resistant variants of Guerin’s carcinoma after 
a single intraperitonealadministration of Feroplat®, were studied on 
an atomic absorption spectrometer C-115M1 (Selmi, Ukraine) with 
an electrothermal atomizer Graphite-2 at lamps with appropriate 
wavelengths (λPt = 265.7 nm, λFe = 248.3 nm). For this purpose, 
samples of the investigated biological tissues were transferred to a 
mineralized form by dry combustion [25].
The area under the pharmacological curve AUC was determined by 
the trapezoidal rule using the formula:
∑
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where ti –time of determination of the agent concentration in 
the animaltissue/blood serum, calculated from the time of drug 
administration; 
Ci– agent concentrartion at time point ti
Therapevtic experiment design
Application of DDP (Cisplatin-Ebewe®) and Feroplat® started from 
the 9th day after tumor transplantation. In therapeutic experiments, 
аnimals were devided into 6 groups according to the agent type 
(Table 1). 
Table 1: Study design and regime specification 
Strain Number of  
animals
Tested
 agent
Code Regime
Sensitive Guerin’s 
carcinoma
10 Control 1 0.5 ml of 199 
medium (Sigma- 
Aldrich, USA)
10 Cisplatin- 
Ebewe®
2 i.v. 5 times (once 
in 2 days); 1.2 mg/
kg of weigh
10 Feroplat® 3 i.v.5times (once in 
2 days); 1.2 mg/kg 
of weight of DDP; 
nanocompos i t e 
particlesize30 - 40 
nm
DDP-resistant 
Guerin’s carcinoma
10 Control 4 0.5 ml of 199 
medium (Sigma- 
Aldrich, USA)
10 Cisplatin- 
Ebewe®
5 i.v.5times (once in 
2 days); 1.2 mg/kg 
of weigh
10 Feroplat® 6 i.v. 5times (once in 
2 days); 1.2 mg/kg 
of weight of DDP; 
nanocomposite 
particle size 30 - 
40 nm
2 days after the last injection of DDP or Feroplat® the euthanasia of 
anaesthetized experimental animals was performed. 
The tumor mass (in grams) was determinedon the electronic balance. 
Tumor volume was calculated by theformula:
V=a•b•c•π/6,
where:а, b, c – orthogonal parameters of tumor.
Percentage of tumor growth inhibition was determined by the 
formula:
Inhibition % = (Control - Experiment)/ Control x 100%,
Where Control and Experiment are indicators of tumor mass or 
volume in the control and therapeutic groups of animals.
Biochemical Analysis of Blood Serum 
After animals’euthanasia, blood sample was put in Heparin 
tubes for biochemical analysis of blood serum. The levels 
of urea, creatinine, and total bilirubin, activities of alanine 
aminotransferase, aspartate aminotransferase, alkaline phosphatase, 
and gammaglutamyltranspeptidase were determined usingthe 
biochemical analyzer (Chem Well, Awarenes Technology, USA).
Morphological Studies 
Small tissue samples from the organs and tumor were fixed in 8% 
neutral buffered formalin, embedded in paraffin, sectioned at 5-6 
mkm thick and stained with haematoxylin-eosin using standard 
histopathological techniques. The sections were examined by light 
microscopy (Primo Star, Carl Zeiss, Germany). 
Statistical Analysis 
All values were expressed as mean ± SD. Results were tested for 
significance with one-way analysis of variance (STATISTICA, v.6). 
P-values < 0.05 were considered statistically significant. Differences 
were consideredreliable at P< 0.05.
Results and Discussion
Pharmacokinetic parameters (АUС24 and Cmax) of platinum (Pt) and 
iron (Fe) in serum, tumor tissue, and organs of experimental animals 
with sensitive (S) and DDP-resistant (R) Guerin’s carcinoma strains 
are presented in Table 2.
Table 2: Pharmacokinetic parameters of iron (Fe) and platinum 
(Pt) in blood serum, tumor and organs of experimental animals 
with sensitive (S) and DDP-resistant (R) Guerin’s carcinoma(n = 10)
Strain AUC24 (Pt), 
μg×h/ml(g)
C
max
(Pt), 
μg/ml
AUC24 (Fe), 
μg×h/ml(g)
C
max
(Fe), μg/
ml
Blood 
serum
S 54.1±14.9 7.3±2.4 189.0±32.9 9.7±1.9
R 313.2±57.0* 28.5±1.9* 256.5±36.6 8.4±0.9
Tumor 
tissue
S 46.5±12.1 7.0±0.7 244.3±38.8 26.9±3.1
R 193.9±31.3* 18.6±1.7* 388.8±14.3* 30.5±2.4
Liver S 152.7±15.0 10.2±0.9 494.8±66.4 30.1±4.1
R 327.6±64.5* 21.1±31* 500.2±108.7 24.6±5.0
Kidney S 78.4±20.8 6.95±0.7 171.2±39.2 17.2±2.1
R 213.7±33.1* 12.0±1.3* 336.0±54.0* 10.9±2.5
*P < 0.05 compared with the sensitiveGuerin’s carcinoma
Table 2 shows that AUC24 (Pt) in serum from rats with a resistant 
tumor was 5.8 times higher than in animals with sensitive strain. In 
the resistant tumors, this parameter was 4.2 times higher (P<0.05) 
compared with the sensitive strain. Similarly, in animals with 
resistant tumors, in comparison to sensitive tumor bearing rats, 
AUC24 (Pt) in the liver and kidneys were 2.1 and 2.7 times higher, 
respectively.
We found no reliable difference between AUC24 (Fe) in serum and 
liver from animals with sensitive and resistant tumors (Table 2). 
However, AUC24 (Fe) in the kidney and tumor increased in animals 
with resistant carcinoma: in 1.6 (tumor) and 2 (kidneys) times 
compared with animals with sensitive tumors (P<0.05).
A significant difference between the AUC24(Fe) in DDP-resistant 
Guerin’s carcinoma may indicate a higher bioavailability of Feroplat® 
for this tumor strain. At the same time, we observed the elevated 
level of AUC24 (Fe) in the liver and kidney of animals with resistant 
strains. An increase in the maximum concentration of C
max
 (Pt) 
(Table 2) can be explained by the shifts in various sectionsof the 
iron exchange that occur in animals with a resistant tumor [26]. 
Moreover, it is known that with the development of drug resistance, 
malignant cells more actively absorb iron ions [27].
The dynamics of the Ptconcentrationchange in the blood serum 
of experimental animals after a single intraperitonealFeroplat® 
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introduction is depicted on Fig.2.
Figure 2: Dynamics of the blood serum Pt concentration changes
Fig. 2 shows that the Ptbioavailability is much higher for animals 
with resistant variant of Guerin’s carcinoma, which contributed to 
the higher accumulation of this element in the tumor, kidneys, and 
liver. The saturation curves for both the sensitive and the resistant 
strains of Guerin’s carcinoma reache a maximum 1 hour after the 
Feroplat®  introduction.
It is important to note the multidirectional dynamics of iron 
accumulation in rats with resistant variant of Guerin’s carcinoma 
(Fig. 3). The maximum concentration was observed 1 hour after 
the Feroplat® administration. At the same time, in blood serum of 
animals with sensitive Guerin’s carcinoma, the increase in iron 
concentration began only 3 hours after the Feroplat®  introduction, 
which may indicate the significant differences in the needs of Fe 
ions, and the peculiarities of its depositing in animals with different 
DDP sensitivitytumors.
Figure 3: Dynamics of the blood serum iron concentration changes
Curves of tumor tissue Pt saturation reach maximum 1 hour after 
Feroplat® injectionin both sensitive and DDP-resistant Guerin’s 
carcinoma (Fig. 4).However, it is evident that the saturation rate 
for the resistant tumor strain is almost 4 times higher compared 
to the sensitive strain (Table 2). Over time, the Ptconcentration 
synchronously decreased,howeverin the resistant strain of Guerin’s 
carcinoma, it remained significantly higher throughout the study 
period.
Figure 4: Dynamics of the tumor tissue Pt concentration changes
Concerning the accumulation of Fe ions in the tumor tissue, this 
index variedsimilarly to its kinetics in blood serum. In animals with 
DDP-resistant Guerin’s carcinoma, iron faster got into the tumor, the 
saturation curve reachedits maximum 30 minutes after the Feroplat® 
introduction (Fig. 5). While in the case of the sensitive strain, the 
maximum of the saturation curve was observed only 3 hours after 
the drug introduction.
Figure 5: Dynamics of the tumor tissue iron concentration changes
Regarding the accumulation of Pt in the liver, in tumor-bearing 
animals of both strains of Guerin’s carcinoma, the same behavior of 
the saturation curve was observed, which reacheditsmaximum 1 hour 
after the Feroplat® introduction (Fig. 6), however, the elimination 
dynamics in animals with DDP-resistant Guerin’s carcinoma was 
significantly higher.
Figure 6: Dynamics of the liverPt concentration changes
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In animals with both Guerin’s carcinoma strains the iron saturation 
curves in the liver were similar and were characterized by a slight 
increase 30 minutes after the Feroplat® introduction and reached 
maximal values 6 hours after injection (Fig. 7).
Figure 7: Dynamics of the liver iron concentration changes
It is known that the effectiveness of antitumor action of DDP is 
substantially limited to its nephrotoxicity, which directly correlates 
with both the maximum concentration of Pt in the kidneys and 
the amount of drug that passes through them. The analysis of 
Ptbiodistribution in tkidneys showed that the Ptaccumulationwas 
higher inrats with DDP-resistant Guerin’s carcinoma (Table 2). For 
animals with both strains of Guerin’scarcinomaitwaas typical the 
presence of Ptsaturation peak 30 and 180 minutes after the Feroplat® 
introduction(Fig. 8).
Figure 8: Dynamics of the kidneyPt concentration changes
In animals with sensitive Guerin’s carcinoma the maximum iron 
accumulation in the kidneys was observed 30 minutes after the 
Feroplat®  introduction (Fig. 9), followed by its decrease. While in 
animals with DDP-resistant Guerin’s carcinoma, the maximum of the 
saturation curve in the kidneys was observed only 6 hours after the 
nanocompositeintroduction, which may contribute to optimizing even 
modern chemotherapeutic regimens aimed atnephrotoxicityreducing.
Figure 9: Dynamics of the kidney iron concentration changes
It is known that the targets for nanocomposites are biological 
macromolecules (DNA, RNA, Proteins), biological membranes, 
and oxidation-reduction systems, which damage can cause 
thedysfunction of several organs and systems[28].
As it was previously reported [21], the impact of DDP and 
Feroplat®  leads to a significant increase in serum creatinine levels in 
experimental animals with sensitive Guerin’s carcinoma. Treatment 
of DDP-resistant Guerin’s carcinoma animals with Feroplat®  and 
Cisplatin-Ebewe® a comparison drug) also resulted in the serum 
creatinineincrease (Table 3). However, no significant differences 
were found between the animals receiving DDP and Feroplat® 
in relation to this index. Regarding other studied biochemical 
parameters, none differences between the groups were noticed 
(Table 3).
Table 3: Blood serum biochemical indexesof rats with DDP-resistant Guerin’s carcinoma after Cisplatin-Ebewe®  and Feroplat® 
introduction (n = 10)
Blood serum biochemical indexes
Urea level,mmol/l Creatininelevel,Μmol/l Aspartate  
aminotransferase 
activity, unit/l 
aspartate
Alanine  
aminotransferase 
activity,
unit/l alanine
Alkaline phosphatase 
activity,unit/l
Gamma 
glutamyl 
transpeptidase 
activity,
unit/l
Total bilirubin 
level, 
μmol/l
Control 16.8 ± 3.0 40.2 ± 2.7 505.0 ± 50.0 60.6 ± 3.0 300.5 ± 40.5 8.3 ± 1.0 10.2 ± 0.9
Cisplatin-Ebewe® 19.5 ± 3.2 70.0 ± 7.0 * 512.0 ± 65.0 57.7 ± 4.0 285.0 ± 42.3 8.5 ± 0.9 11.0 ± 1.1
Feroplat® 17.7 ± 3.0 63.1 ± 6.3 * 490.0 ± 60.0 49.0 ± 3.7 295.5 ± 45.0 8.0 ± 1.0 10.6 ± 0.8
Note: * - the indicator is significantly different from that in the control(P< 0,05).
Thus, according to the blood biochemical indexes, Feroplat® exhibitedtheside effect similar to that of Cisplatin-Ebewe® .
At the next stage of the study, it was explored how the pharmacokinetics of Feroplat®  may affect its antitumor activity. The antitumor 
effect of Feroplat®  on sensitive Guerin’s carcinoma is shown in Table 4. Cisplatin-Ebewe®  and Feroplat®  virtually almost equally 
inhibited the growth of sensitive tumors. However, in the therapeutic experiments with DDP-resistant Guerin’s carcinoma, Cisplatin-
Ebewe®  had virtually no effect on tumor growth, while Feroplat® 
led to the tumor growth inhibition by 41% of volume and by 43% 
of weight (Fig. 10).
Table 4: Antitumor activity of Feroplat®  and DDP on sensitive 
Guerin’s carcinoma (n = 10)
Animal group Tumor volume Inhibition, %
Control (sm3) -
Cisplatin-Ebewe® 18.5±1.4 88
Feroplat® 2.2±0.5* 90
1.9±0.3*
Note:*P<0.05 compared with the control
Figure 10: Antitumor activity of Feroplat®  and Cisplatin-Ebewe® 
(A - by volume: B - by weight) on DDP-resistant Guerin’s carcinoma 
(n = 10).
Studies of the morphological features of the DDP-resistant Guerin’s 
carcinoma architectonics in the rats from control group that were 
not exposed to Cisplatin-Ebewe®  or Feroplat®  showed that the 
major part of the tumors were thecells characterized by moderately 
pronounced polymorphism with a solid growth pattern. The cells had 
elongated or rounded form, the cytoplasm with signs of basophilia, 
large nuclei, some of which were located eccentrically (Fig. 11A). 
Often there were figures of mitotic division. There were small mosaic 
patterns of the non-fibrotic and necrotic cells death (Fig. 11B).
Thecharacteristic morphological distinction ofDDP-resistant 
Guerin’s carcinoma treated with Cisplatin-Ebewe® was that, on 
the background of the overall structure of the tumor, which did 
not differ from the control, certain cells with signs of treatment 
pathomorphism were detected (Fig. 11C). Along with this, there 
were the necrosis and necrobiosis fields of different sizes (Fig. 11 
D). It should be noted that in all tumors exposed to Cisplatin-Ebewe® 
, a large number of mitoses, including pathological, were detected.
Comparative studies showed that in DDP-resistant Guerin’s carcinoma 
Feroplat®  caused more pronounced variety of the spectrum and 
the degree of manifestation of therapeutic pathomorphosis. Along 
with the formation of giant cells, the cytomorphological effects in 
the tumors of animals treated with Feroplat®  were characterized 
by the fact that among the layers of compactly located cells that 
were almost identical to the cells obtained from control animals, 
individual patterns were determined, as well as significant sheets 
of the tumor cells with pronounced signs of hydropic degeneration 
of the cytoplasm and nuclei. With a large number of these cells, 
honeycomb look-alike structures were formed (Fig. 11E). 
We found thesignificant decrease in the number of mitoses figures. 
Along with this, extensive fields of necrobiotic cell death, necrosis, 
theremnantsof dead apoptotic cells were determinedin the various 
sites of tumors. In some animals, thin-walled blood capillaries were 
found among dystrophic and non-fibrotically altered tumor cells, filled 
with blood, and we observed extensive hemorrhages (Fig. 11 F, 11 G). 
Thedistinctive feature of the tumors after Feroplat®  introduction was 
that in some cells along with dead cells we found the phenomenon of 
the fibrous organization of the structurally altered tumor tissue which 
expressiveness had different degree(Fig. 11H, 11I).
Figure 11A: Thesolid character of tumor growth and the tumor cells 
compact location of DDP- resistant Guerin’s carcinoma (control) 
(×200)
Figure 11B: Figures of mitoses, including atypical, in tumor cells 
of DDP-resistant Guerin’s carcinoma (control) (×1000)
Figure 11C: Formation of "giants of medical pathomorphosis" in 
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the DDP-resistant Guerin’scarcinomaunderthe Cisplatin-Ebewe® 
influence (×200)
Figure 11D: Pattern of tumor cells with signs of necrobiosis (on 
the right) was bordered by a pattern of necrotic cells (on the left). 
Action of Cisplatin-Ebewe®  (×200)
Figure 11E: Formation of honeycomb look-alike structures as a 
consequence of vacuolo-hydroponic dystrophy of DDP-resistant 
Guerin’scarcinoma cells under the Feroplat®influence (×200).
Figure 11F: Among the dystrophically altered cells of DDP-resistant 
Guernine carcinoma, there were a lot ofthin-walled blood capillaries 
filled with blood after the Feroplat® influence (×200)
Figure 11G: Intervention of strains and patterns of tumor cells in 
the state of nebrobiosis and necrosis with a large number of delated 
capillaries filled with blood undertheFeroplat® influence (×100).
Figure 11H: Initial phenomena of fibrous organization of the center 
of dead cells, including apoptosis after the Feroplat® influence (×100).
Figure 11I: Expressed signs of substituting necrobioticalo broken 
cells with soft-fibrous connective tissue after the influence of 
Feroplat® (×200)
Fig.11 Changes in the cytoarchitectonics of DDP-resistant Guerin’s 
carcinoma under the influence of Cisplatin-Ebewe and Feroplat® 
(coloring with hematoxylin and eosin).
Along with the pronounced signs of pathomorphosiscausedbyFeroplat® 
among the necrotic zones, there were recovery processes, namely, 
the elements of the fibrous organization inthetumorfocus.
Thus, the resulted of the conducted studies have shown that significant 
differences in the pharmacokinetics of Feroplat®contributed to the 
selectivity of its accumulation in the organs and tissues, thatallowedto 
achieve the significant antitumor effect in the case of DDP-resistant 
Guerin’s carcinoma.
Conclusion
1. Pharmacokinetic studies have shown that the ferromagnetic 
nanocomposite (Feroplat®) is more intensively accumulated 
in DDP-resistant tumors compared with the sensitive Guerin’s 
carcinoma. Its’ maximum concentration in the resistant tumor 
was 2.6 times higher than in the sensitive strain. This leads 
to the fact that Feroplat® exhibits a higher antitumor activity 
ontheresistant Guerin’s carcinoma.
2. Under the Feroplat® influence the most significant 
cytomorphological effects and manifestations of signs of 
treatmentpathomorphosis are observed in cells of theDDP-
resistant Guerin’s carcinoma.
3. Thesignificant increase in the antitumor effect of Feroplat® 
in animals with DDP-resistant Guerin’s carcinoma may be 
associated not only with increased bioavailability but also with 
the involvement of its additional mechanisms associated with 
Fe ions as a source of oxidative stress in the tumor.
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